Pacira BioSciences, Inc. - Common Stock, par value $0.001 per share (PCRX)

Historical Holders from Q1 2014 to Q3 2025

Symbol
PCRX on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
42.9M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
48M
Holdings value
$1.24B
% of all portfolios
0.004%
Grand Portfolio weight change
0%
Number of holders
235
Number of buys
100
Number of sells
-126
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Pacira BioSciences, Inc. - Common Stock, par value $0.001 per share (PCRX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15.2% $189M 7.02M BlackRock, Inc. 31 Mar 2025
Doma Perpetual Capital Management LLC 6.83% +18.8% $75.7M $6.14M 2.94M +8.83% Doma Perpetual Capital Management LLC 06 Nov 2025
RENAISSANCE TECHNOLOGIES LLC 4.98% -7.2% $55.1M -$6.63M 2.14M -10.7% Renaissance Technologies LLC 01 Jul 2025
Pacer Advisors, Inc. 1.28% -80.7% $16.2M -$71.9M 602K -81.6% Pacer Advisors, Inc. 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 0.7% -88% $9.33M -$53.8M 346K -85.2% Millennium Management LLC 31 Mar 2025

Institutional Holders of Pacira BioSciences, Inc. - Common Stock, par value $0.001 per share (PCRX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 48M $1.24B -$66.5M $25.77 235
2025 Q2 50.5M $1.21B -$360K $23.90 230
2025 Q1 50.6M $1.26B +$32.6M $24.85 234
2024 Q4 49.9M $941M -$17M $18.84 229
2024 Q3 51.3M $772M -$166M $15.05 235
2024 Q2 51.9M $1.49B +$74.7M $28.61 274
2024 Q1 49.1M $1.44B +$18.7M $29.22 267
2023 Q4 48.3M $1.63B -$9.89M $33.74 257
2023 Q3 47.5M $1.46B -$4.48M $30.68 257
2023 Q2 47M $1.88B +$21.5M $40.07 253
2023 Q1 46.4M $1.89B -$75.5M $40.81 265
2022 Q4 48.6M $1.88B -$89.1M $38.61 268
2022 Q3 50.5M $2.69B +$59.3M $53.19 258
2022 Q2 49M $2.85B -$35.6M $58.30 271
2022 Q1 49.6M $3.79B -$42.7M $76.32 288
2021 Q4 50.6M $3.05B +$83M $60.17 264
2021 Q3 49.1M $2.75B -$7.66M $56.00 252
2021 Q2 49.2M $2.99B -$36.5M $60.68 254
2021 Q1 49.8M $3.49B -$29M $70.09 265
2020 Q4 50.4M $3.01B +$131M $59.84 257
2020 Q3 48.3M $2.9B -$13.4M $60.12 255
2020 Q2 48.7M $2.56B +$107M $52.47 241
2020 Q1 47M $1.58B +$37.7M $33.53 216
2019 Q4 45.5M $2.06B +$15.6M $45.30 227
2019 Q3 45.1M $1.72B +$75.4M $38.07 206
2019 Q2 42.8M $1.86B +$105M $43.49 216
2019 Q1 41.3M $1.57B +$29.4M $38.06 203
2018 Q4 40.1M $1.72B -$34.3M $43.02 201
2018 Q3 40.6M $2B -$82.3M $49.15 182
2018 Q2 42.9M $1.37B -$18M $32.05 148
2018 Q1 43.6M $1.36B +$18.7M $31.15 163
2017 Q4 41.9M $1.91B -$62.7M $45.65 180
2017 Q3 43.7M $1.64B +$59.5M $37.55 176
2017 Q2 41.2M $1.97B +$10.4M $47.70 191
2017 Q1 40.9M $1.87B +$211M $45.60 187
2016 Q4 40.3M $1.3B +$16.6M $32.30 178
2016 Q3 39.8M $1.36B -$42.5M $34.22 176
2016 Q2 40.7M $1.37B -$219M $33.73 180
2016 Q1 43.5M $2.31B -$41.7M $52.98 178
2015 Q4 42.6M $3.27B +$18.3M $76.79 211
2015 Q3 42.8M $1.76B -$32.4M $41.10 175
2015 Q2 42.8M $3.03B +$138M $70.72 186
2015 Q1 40.4M $3.59B +$93.1M $88.85 205
2014 Q4 39.2M $3.48B +$20.9M $88.66 198
2014 Q3 38.7M $3.75B +$100M $96.92 205
2014 Q2 37.8M $3.47B +$237M $91.86 190
2014 Q1 35.3M $2.47B +$14.4M $69.99 160